Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response
dc.contributor.author | Loo, C. | |
dc.contributor.author | Alonzo, A. | |
dc.contributor.author | Barton, D. | |
dc.contributor.author | Berk, M. | |
dc.contributor.author | Chatterton, M.L. | |
dc.contributor.author | Dong, V. | |
dc.contributor.author | Gálvez, V. | |
dc.contributor.author | Mills, N.T. | |
dc.contributor.author | Mitchell, P.B. | |
dc.contributor.author | Sarma, S. | |
dc.contributor.author | Somogyi, A.A. | |
dc.contributor.author | Rodgers, A. | |
dc.date.issued | 2025 | |
dc.description | Commentary | |
dc.description.abstract | Abstract is not available | |
dc.description.statementofresponsibility | Colleen Loo, Angelo Alonzo, David Barton, Michael Berk, Mary Lou Chatterton, Vanessa Dong, Veronica Gálvez, Natalie T. Mills, Philip B. Mitchell, Shanthi Sarma, Andrew A. Somogyi, and Anthony Rodgers | |
dc.identifier.citation | The British journal of psychiatry. Supplement, 2025; 226(5):317-318 | |
dc.identifier.doi | 10.1192/bjp.2024.176 | |
dc.identifier.issn | 0007-1250 | |
dc.identifier.issn | 1472-1465 | |
dc.identifier.orcid | Mills, N.T. [0000-0003-3255-5118] | |
dc.identifier.orcid | Somogyi, A.A. [0000-0003-4779-0380] | |
dc.identifier.uri | https://hdl.handle.net/2440/147489 | |
dc.language.iso | en | |
dc.publisher | Cambridge University Press | |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1105089 | |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1195651 | |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1156072 | |
dc.rights | © The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists. | |
dc.source.uri | https://doi.org/10.1192/bjp.2024.176 | |
dc.subject | Ketamine/esketamine; major depressive disorder; clinical drug studies; neuroscience; affective disorders; commentary | |
dc.title | Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response | |
dc.type | Journal article | |
pubs.publication-status | Published |